# Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL

> **NCT02689726** · PHASE1 · TERMINATED · sponsor: **Genticel** · enrollment: 13 (actual)

## Conditions studied

- HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL

## Interventions

- **DRUG:** GTL001+
- **DRUG:** Aldara

## Key facts

- **NCT ID:** NCT02689726
- **Lead sponsor:** Genticel
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Lack of efficacy in European Phase 2 study
- **Last updated:** 2016-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02689726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02689726, "Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02689726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*